NDA for NF1-PN Treatment Charges Ahead with Priority Review
source: shutterstock.com

NDA for NF1-PN Treatment Charges Ahead with Priority Review

According to a press release from GlobeNewswire, the biopharmaceutical company SpringWorks Therapeutics recently announced that the US Food and Drug Administration (FDA) has granted the company's New Drug Application (NDA)…

Continue Reading NDA for NF1-PN Treatment Charges Ahead with Priority Review